-
1
-
-
49749147563
-
Both EGfR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels
-
Zhang, D.Y., Wang, Y., Lau, C.P., Tse, H.F. & Li, G.R. Both EGfR kinase and Src-related tyrosine kinases regulate human ether-à-go-go- related gene potassium channels. Cell Signal. 20, 1815-1821 (2008).
-
(2008)
Cell Signal.
, vol.20
, pp. 1815-1821
-
-
Zhang, D.Y.1
Wang, Y.2
Lau, C.P.3
Tse, H.F.4
Li, G.R.5
-
2
-
-
75749120735
-
Experience in QT evaluation of oncology drug products since ICH E14 guidance. Proceedings of 2008 american Society of Clinical Oncology annual Meeting
-
May 20 suppl. abstract 2554
-
Liu, Q., Madabushi, R., Garnett, C. & Booth, B. Experience in QT evaluation of oncology drug products since ICH E14 guidance. Proceedings of 2008 american Society of Clinical Oncology annual Meeting, J. Clin. Oncol. 26 (May 20 suppl.), (2008). abstract 2554
-
(2008)
J. Clin. Oncol.
, vol.26
-
-
Liu, Q.1
Madabushi, R.2
Garnett, C.3
Booth, B.4
-
3
-
-
33745725793
-
Cardiac safety, risk management, and oncology drug development
-
fingert, H.J. & Varterasian, M.L. Cardiac safety, risk management, and oncology drug development. Clin. Cancer Res. 12, 3646-3647 (2006).
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 3646-3647
-
-
Fingert, H.J.1
Varterasian, M.L.2
-
4
-
-
34548276036
-
Molecularly targeted oncology therapeutics and prolongation of the QT interval
-
Strevel, E.L., Ing, D.J. & Siu, L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25, 3362-3371 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 3362-3371
-
-
Strevel, E.L.1
Ing, D.J.2
Siu, L.L.3
-
5
-
-
35348925070
-
Evaluation of the efect on cardiac repolarization (QTc interval) of oncologic drugs
-
Morganroth, J. Evaluation of the efect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res. Found. Workshop 59, 171-184 (2007).
-
(2007)
Ernst Schering Res. Found. Workshop
, vol.59
, pp. 171-184
-
-
Morganroth, J.1
-
6
-
-
40249094483
-
Drug-induced QTc interval prolongation: A proposal towards an efcient and safe anticancer drug development
-
Curigliano, G. et al. Drug-induced QTc interval prolongation: a proposal towards an efcient and safe anticancer drug development. Eur. J. Cancer 44, 494-500 (2008).
-
(2008)
Eur. J. Cancer
, vol.44
, pp. 494-500
-
-
Curigliano, G.1
-
7
-
-
44949175102
-
Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents
-
Sarapa, N. & Britto, M.R. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin. Drug Saf. 7, 305-318 (2008).
-
(2008)
Expert Opin. Drug Saf.
, vol.7
, pp. 305-318
-
-
Sarapa, N.1
Britto, M.R.2
-
8
-
-
64349093768
-
Assessing proarrhythmic potential of drugs when optimal studies are infeasible
-
Rock, E.P. et al. assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am. Heart J. 157, 827-36, 836.e1 (2009).
-
(2009)
Am. Heart J.
, vol.157
-
-
Rock, E.P.1
-
9
-
-
75749156715
-
The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
-
Committee for Medicinal Products for Human Use. ICH Note for Guidance on EMEa, London, 25 May
-
Committee for Medicinal Products for Human Use. ICH Note for Guidance on "The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals" (ICH S7B) (CHMP/ICH/423/02) EMEa, London, 25 May 2005.
-
(2005)
(ICH S7B) (CHMP/ICH/423/02)
-
-
-
11
-
-
36749056453
-
HERG channel trafcking: Novel targets in drug-induced long QT syndrome
-
Dennis, a., Wang, L., Wan, X. & ficker, E. hERG channel trafcking: novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans. 35, 1060-1063 (2007)
-
(2007)
Biochem. Soc. Trans.
, vol.35
, pp. 1060-1063
-
-
Dennis, A.1
Wang, L.2
Wan, X.3
Ficker, E.4
-
12
-
-
54849435649
-
Inhibition of hERG channel trafcking: An under-explored mechanism for drug-induced QT prolongation
-
yeung, K.S. & Meanwell, N.a. Inhibition of hERG channel trafcking: an under-explored mechanism for drug-induced QT prolongation. ChemMedChem. 3, 1501-1502 (2008).
-
(2008)
Chem Med Chem.
, vol.3
, pp. 1501-1502
-
-
Yeung, K.S.1
Meanwell, N.A.2
-
13
-
-
50049083789
-
The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes
-
Carlsson, L. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol. Ther. 119, 160-167 (2008)
-
(2008)
Pharmacol. Ther.
, vol.119
, pp. 160-167
-
-
Carlsson, L.1
-
14
-
-
48149111313
-
Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts
-
Sugiyama, A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol. 154, 1528-1537 (2008).
-
(2008)
Br. J. Pharmacol.
, vol.154
, pp. 1528-1537
-
-
Sugiyama, A.1
-
15
-
-
33644823249
-
Amplifcation of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes
-
Antzelevitch, C. & Oliva, a. amplifcation of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. J. Intern. Med. 259, 48-58 (2006).
-
(2006)
J. Intern. Med.
, vol.259
, pp. 48-58
-
-
Antzelevitch, C.1
Oliva, A.2
-
16
-
-
21344463329
-
Refning detection of drug-induced proarrhythmia: QT interval and TRIaD
-
Shah, R.R. & Hondeghem, L.M. Refning detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2, 758-772 (2005)
-
(2005)
Heart Rhythm
, vol.2
, pp. 758-772
-
-
Shah, R.R.1
Hondeghem, L.M.2
-
17
-
-
48149096544
-
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model
-
yao, X. et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456 (2008).
-
(2008)
Br. J. Pharmacol.
, Issue.154
, pp. 1446-1456
-
-
Yao, X.1
-
18
-
-
44349105190
-
Evaluating the QT-liability of a drug during its development
-
Shah, R.R. & Morganroth, J. Evaluating the QT-liability of a drug during its development. Pharm. Med. 22, 151-164 (2008).
-
(2008)
Pharm. Med.
, vol.22
, pp. 151-164
-
-
Shah, R.R.1
Morganroth, J.2
-
19
-
-
0025825919
-
Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia
-
Morganroth, J., Brozovich, F.V., McDonald, J.T. & Jacobs, R.A. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am. J. Cardiol. 67, 774-776 (1991).
-
(1991)
Am. J. Cardiol.
, vol.67
, pp. 774-776
-
-
Morganroth, J.1
Brozovich, F.V.2
McDonald, J.T.3
Jacobs, R.A.4
-
20
-
-
0141576728
-
Baseline heart rate-corrected QT and eligibility for clinical trials in oncology
-
Varterasian, M. et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J. Clin. Oncol. 21, 3378-3379 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3378-3379
-
-
Varterasian, M.1
-
21
-
-
75749138651
-
Risk management and eligibility criteria for QTc assessment in patients with advanced cancer. Proceedings of 2005 american Society of Clinical Oncology annual Meeting
-
(June 1 suppl.), 16S, Part I of II (2005). abstract 3047
-
Sarapa, N., Huang, X., Varterasian, M. & fingert, H. Risk management and eligibility criteria for QTc assessment in patients with advanced cancer. Proceedings of 2005 american Society of Clinical Oncology annual Meeting, J. Clin. Oncol. 23 (June 1 suppl.), 16S, Part I of II (2005). abstract 3047
-
J. Clin. Oncol.
, vol.23
-
-
Sarapa, N.1
Huang, X.2
Varterasian, M.3
Fingert, H.4
-
22
-
-
34247580900
-
QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines
-
Arbel, y., Swartzon, M. & Justo, D. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs 18, 493-498 (2007).
-
(2007)
Anticancer Drugs
, vol.18
, pp. 493-498
-
-
Arbel, Y.1
Swartzon, M.2
Justo, D.3
-
23
-
-
0029883856
-
Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug efect from spontaneous variability
-
Pratt, C.M. et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug efect from spontaneous variability. Am. Heart J. 131, 472-480 (1996).
-
(1996)
Am. Heart J.
, vol.131
, pp. 472-480
-
-
Pratt, C.M.1
-
24
-
-
39749192587
-
The diagnosis and management of cardiovascular disease in cancer patients
-
Yusuf, S.W., Razeghi, P. & yeh, E.T. The diagnosis and management of cardiovascular disease in cancer patients. Curr. Probl. Cardiol. 33, 163-196 (2008).
-
(2008)
Curr. Probl. Cardiol.
, vol.33
, pp. 163-196
-
-
Yusuf, S.W.1
Razeghi, P.2
Yeh, E.T.3
-
25
-
-
33645728030
-
Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?
-
Van Heeckeren, W.J. et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol. 24, 1485-1488 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1485-1488
-
-
Van Heeckeren, W.J.1
|